ARTICLE | Clinical News
INS37217 denufosol tetrasodium: Phase III started
February 18, 2008 8:00 AM UTC
Inspire began the double-blind, international Phase III TIGER-2 trial to evaluate 60 mg of inhaled denufosol tetrasodium given thrice daily vs. placebo in about 350 patients for 24 weeks. Patients are...